about
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health CentreA well-being support program for patients with severe mental illness: a service evaluation.Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?Blood lactate levels in patients receiving first- or second- generation antipsychotics.The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis.Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional studySTRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications.Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPDEffect of Early Intervention with Omega-3 on Insulin Resistance in Patients Initiated on Olanzapine with either Sodium Valproate or Lithium: A randomized, Double-blind, Placebo-Controlled Trial.Local Anesthetics and Antipsychotic Phenothiazines Interact Nonspecifically with Membranes and Inhibit Hexose Transporters in Yeast.A case series: evaluation of the metabolic safety of aripiprazoleDo psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures?Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.Pancreatitis and diabetic ketoacidosis with quetiapine useDyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria.Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.Potential Association Between Risperidone and Cerebrovascular EventsMetabolic changes associated with antipsychotic useThe challenge of recruiting people with schizophrenia to a health promotion trial.
P2860
Q33236751-04AD60C2-72AA-44B4-BF75-3EE4287010ABQ33850375-DD8D0A64-14CD-45B4-9D79-71F06F7A0FC1Q33942644-ADB0B89A-B2C3-4442-8EB2-85FE7139EDF3Q34054063-0D0791A7-60F0-414B-A394-D955CDE3B96FQ34183495-19DD5D42-8318-4D9D-B0F8-04178DCC233BQ34613859-18D14760-CB62-44D8-90E0-11882D9B3D43Q34634068-7CF34BC0-54FD-4EA4-9227-96EFD31F1786Q34944648-5FAC386A-7F20-456D-AC7B-977D59648CB7Q35001376-FF63D379-FEB0-4C69-94C2-00650FDBC9C5Q35732364-2E0CE6FD-2751-43B6-B39D-9AE3D2D72A74Q36197756-FCB539AF-790F-49EF-9F27-1BDDAE1F3566Q36677156-077AE3A3-F088-4CA0-AF17-F6C18C59E259Q36853249-720D40DD-1121-4220-9C84-6BEF87D5213AQ37170963-46165D55-5842-4B6F-8967-B701AA5EB06FQ37189197-B6E953FC-B398-4FB3-BFA3-1D9B1534B111Q37285348-830A8A03-DB6A-42D8-B0A6-A33D005E29D7Q37681620-D0633D4A-8FD2-4E11-B160-70210BCC86ABQ40050322-D22B704D-6712-472C-B4C1-D95611AF1F44Q40841340-AFA6768F-575A-492D-A07D-BD47BE98D575Q41359319-58653B0E-DDAD-42EF-BBB8-190F8A016F43Q42128215-18506652-FDE6-470B-9741-C3AA37129771
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hyperglycemia and antipsychotic medications.
@ast
Hyperglycemia and antipsychotic medications.
@en
Hyperglycemia and antipsychotic medications.
@nl
type
label
Hyperglycemia and antipsychotic medications.
@ast
Hyperglycemia and antipsychotic medications.
@en
Hyperglycemia and antipsychotic medications.
@nl
prefLabel
Hyperglycemia and antipsychotic medications.
@ast
Hyperglycemia and antipsychotic medications.
@en
Hyperglycemia and antipsychotic medications.
@nl
P1476
Hyperglycemia and antipsychotic medications
@en
P2093
P304
15-26; discussion 40-1
P478
62 Suppl 27
P577
2001-01-01T00:00:00Z